No crucial area in pharma is more desperately in need of a fix — or more stubbornly resistant to change.
Merck CEO Kenneth Frazier’s exit from a presidential manufacturing council may go down as one of the most principled stands by the CEO of a major U.S. company, let alone a drugmaker.
Despite approvals of competing products from AbbVie, Merck, and Bristol-Myers Squibb, Gilead remains the market leader.
Alone among the best-known social platforms, Snapchat has failed to generate much enthusiasm from pharma. Here’s why — and here’s why that may change.
Dengvaxia’s post-launch plight reflects the difficulties of launching a vaccine. Is this a harbinger for future vaccine-marketing efforts?
Pfizer’s Prevnar tops the list, according to data compiled by EvaluatePharma.
He was diagnosed years ago with a handful of autoimmune conditions, treating them with drugs like Abbvie’s Humira, which he helped commercialize.